Clinical trial
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With…
NCT00019448 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019448 |
|---|---|
| Title | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma |
| Official title | Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma, Recurrent Melanoma |
| Intervention type | Drug |
| Interventions | gp100 antigen, interleukin-2 |
| Start date | Sep 1, 1998 |
| Completion | Mar 1, 2007 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: